{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T19:36:00Z","timestamp":1767987360726,"version":"3.49.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.clml.2021.07.006","type":"journal-article","created":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T12:17:02Z","timestamp":1626092222000},"page":"e929-e937","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Outcomes Related to FDG-PET-CT Response in Patients With Hodgkin Lymphoma Treated With Brentuximab-Vedotin at Relapse or Consolidation"],"prefix":"10.1016","volume":"21","author":[{"given":"Meirav","family":"Kedmi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavel","family":"Khaustov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Ribakovsy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ohad","family":"Benjamini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abraham","family":"Avigdor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2021.07.006_bib0001","first-page":"20","article-title":"FDG-PET imaging for Hodgkin lymphoma: current use and future applications","volume":"12","author":"Kostakoglu","year":"2014","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.clml.2021.07.006_bib0002","first-page":"482","article-title":"Position emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma","volume":"91","author":"Hutchings","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.07.006_bib0003","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/cncr.21253","article-title":"A metaanalysis of 18F-2-deoxy-2-fluoro-d-glucose positron emission tomography in the staging and restaging of patients with lymphoma","volume":"104","author":"Isasi","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2021.07.006_bib0004","doi-asserted-by":"crossref","first-page":"347","DOI":"10.6004\/jnccn.2010.0023","article-title":"An update on the role of interim restaging FDG-PET in patients with diffuse large B-cell lymphoma and Hodgkin lymphoma","volume":"8","author":"Moskowitz","year":"2010","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2021.07.006_bib0005","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2005-06-2252","article-title":"FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma","volume":"107","author":"Hutchings","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.006_bib0006","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1200\/JCO.2007.11.6525","article-title":"Early interim 2-[18F]fluoro-2-deoxy-d-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study","volume":"25","author":"Gallamini","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.07.006_bib0007","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2967\/jnumed.112.110890","article-title":"International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers","volume":"54","author":"Biggi","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1016\/j.clml.2021.07.006_bib0008","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/ajh.25071","article-title":"Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management","volume":"93","author":"Ansell","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2021.07.006_bib0009","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/hon.2589","article-title":"Treating Hodgkin lymphoma in the new millennium: relapsed and refractory disease","volume":"37","author":"LaCasce","year":"2019","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2021.07.006_bib0010","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1182\/blood-2011-10-388058","article-title":"Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma","volume":"119","author":"Moskowitz","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.006_bib0011","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00259-017-3690-8","article-title":"FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas","volume":"44","author":"Barrington","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clml.2021.07.006_bib0012","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.07.006_bib0013","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2021.07.006_bib0014","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma","volume":"378","author":"Connors","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.07.006_bib0015","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","article-title":"Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma","volume":"128","author":"Chen","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.006_bib0016","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/jjco\/hyu204","article-title":"Recent advances in Hodgkin lymphoma: interim PET and molecular-targeted therapy","volume":"45","author":"Nagai","year":"2015","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.clml.2021.07.006_bib0017","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1136\/jnnp-2020-323124","article-title":"Brentuximab vedotin treatment associated with acute and chronic inflammatory demyelinating polyradiculoneuropathies","volume":"91","author":"Fargeot","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.clml.2021.07.006_bib0018","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2021.07.006_bib0019","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1080\/10428194.2019.1605068","article-title":"Clinical and neurophysiological serial assessments of brentuximab vedotin-associated peripheral neuropathy","volume":"60","author":"Mariotto","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.07.006_bib0020","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.07.006_bib0021","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1182\/blood-2018-07-861641","article-title":"Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse","volume":"132","author":"Moskowitz","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.006_bib0022","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1182\/blood-2014-08-595801","article-title":"Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma","volume":"125","author":"Gopal","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.006_bib0023","article-title":"After failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205","volume":"362018","year":"2021","journal-title":"Trial Vol"},{"key":"10.1016\/j.clml.2021.07.006_bib0024","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S1470-2045(21)00005-X","article-title":"Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study","volume":"22","author":"Kuruvilla","year":"2021","journal-title":"Lancet Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021002767?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021002767?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:38:29Z","timestamp":1761871109000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265021002767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S2152265021002767"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2021.07.006","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes Related to FDG-PET-CT Response in Patients With Hodgkin Lymphoma Treated With Brentuximab-Vedotin at Relapse or Consolidation","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2021.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}